Real‐World Outcomes of Venetoclax and Azacitidine in Hospitalized Patients With Acute Myeloid Leukemia: A Retrospective Study at a Tertiary Care Center
Venetoclax plus azacitidine improves survival in older or unfit patients with newly diagnosed acute myeloid leukemia (AML), as demonstrated in the VIALE‐A trial. 2 However, real‐world data in hospitalized patients—particularly those with secondary AML or adverse‐risk mutations—remain limited. We conducted a retrospecti...